Public Company News

Unveil the Magic of Fall with Suika Game's '[Autumn Version] Special Skin Pack'

TOKYO, Sept. 17, 2024 /PRNewswire/ -- Aladdin X Inc., a subsidiary of the award-winning projector and laser projector brandXGIMI , is celebrating the autumn with the global launch of the '[Autumn Version] Special Skin Expansion Pack' onSeptember 17th. This pack allows play...

2024-09-17 09:00 5246

Sinch Accelerates Adoption of Rich Communication Services (RCS) Business Messaging with RCS Upscale

Leading the Evolution of Customer Engagement with Secure, Interactive, and Branded Messaging Across Devices & Platforms ATLANTA and STOCKHOLM, Sept. 17, 2024 /PRNewswire/ -- Sinch (Sinch AB (publ) – XSTO: SINCH), which is pioneering the way the world communicates through its Customer Communicati...

2024-09-17 02:51 5888

Harvard Business School examines DBS' AI strategy and implementation in its first case study focusing on AI in an Asian bank

Authored by Feng Zhu, HBS Professor of Business Administration, the case highlights the bank's use of AI and takeaways for companies navigating technological change SINGAPORE, Sept. 16, 2024 /PRNewswire/ -- Harvard Business School (HBS) has published a case study on DBS' strategy towards Artific...

2024-09-16 22:00 4831

Intelligent Living Application Group Inc. Regains Compliance with Nasdaq's Minimum Bid Price Rule

HONG KONG, Sept. 16, 2024 /PRNewswire/ -- Intelligent Living Application Group Inc. (NASDAQ:ILAG ) ("Intelligent Living"...

2024-09-16 21:00 6070

Concord Medical Announces Obtaining Large Medical Equipment Procurement License for Its Proton Therapy Equipment

BEIJING, Sept. 16, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that Guangzhou Concord Cancer Center ("Guangzhou H...

2024-09-16 20:00 3478

Game-Changing Lidar OT128 from Hesai Unveiled at IAA Transportation, Accelerating Autonomous Vehicles' Commercial Deployment

HANNOVER, Germany, Sept. 16, 2024 /PRNewswire/ -- Hesai Technology (Nasdaq: HSAI), the global leader in lidar technology, is launching its powerful new lidar solution OT128 atEurope's biggest commercial vehicle trade fair IAA Transportation inHannover (booth location: Hall 12, #C71). Hesai's OT12...

2024-09-16 20:00 2618

Vazyme Leads Life Science Innovation, Boosting Research Breakthroughs in mIDH1 Cancer Treatment

NANJING, China, Sept. 16, 2024 /PRNewswire/ -- Vazyme (688105.SH), a leading life science technology company, significantly contributed to groundbreaking research published in Science Magazine through its innovative products. The study, which focuses on how mutant IDH1 inhibition activates tumor ...

2024-09-16 19:00 3084

Antennova Releases Latest Data of CD73 Inhibitor ATN-037, including a DCR of 89.5%, in a Mini Oral at ESMO Congress 2024

* In patients with non-small cell lung cancer (NSCLC) or melanoma who had acquired resistance to checkpoint inhibitors (CPIs), ATN-037 in combination with KEYTRUDA®(pembrolizumab) demonstrated an overall response rate (ORR) of 21.1% and a disease control rate (DCR) of 89.5%. * Data from the...

2024-09-16 18:00 3439

China Automotive Systems Announces Annual Meeting on September 24, 2024

CAAS announces the conference call and webcast information for the Annual Meeting of Stockholders to be held onTuesday, September 24, 2024 at 9:00 AM local time, or 9:00 PM EDT onMonday, September 23, 2024 WUHAN, China, Sept. 16, 2024 /PRNewswire/ -- China Automotive Systems, Inc. (Nasdaq: CAAS)...

2024-09-16 18:00 5679

Akeso's Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety at ESMO 2024

HONG KONG, Sept. 16, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) published the phase 2 results from its ivonescimab in combination with chemotherapy as a first-line (1L) treatment for triple-negative breast cancer (TNBC). The prelimina...

2024-09-16 15:35 6051

Autoliv Appoints Adriana Karaboutis to its Board of Directors

STOCKHOLM, Sept. 16, 2024 /PRNewswire/ -- Autoliv, Inc. (NYSE: ALV) (SSE: ALIVsdb), the worldwide leader in automotive safety systems, announces that it has added a new independent member to its Board of Directors effective today. On September 13, 2024, the Autoliv Board of Directors appointed Ms...

2024-09-16 14:53 3002

Alphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024

SUZHOU, China, Sept. 16, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from two studies on anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 were presented at the 2024 European Society for Medical Oncology Congress (ESMO Congress 202...

2024-09-16 13:03 3199

Risen Energy Champions Environmental Stewardship for a Greener Future

NINGBO, China, Sept. 15, 2024 /PRNewswire/ -- On September 20, World Cleanup Day 2024 kicks off during the Clean Up the World Weekend (CUW Weekend), themed "make room for life." Since joining the UN Global Compact (UNGC) in 2021, Risen Energy, a leader in global photovoltaic (PV) innovation, has ...

2024-09-16 10:00 3404

Temple Mall Presents "Blue-and-White Porcelain Impressions" Art Experience

Collaborating with Local Artist Angel Hui to Explore the Beauty of a Millennia-old Cultural Treasure * Temple Mall presents a themed event and exhibition celebrating blue-and-white porcelain, inviting the public to explore and appreciate the rich heritage of this millennia-old cultural treasur...

2024-09-16 09:00 4291

Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024

Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso released the Phase 2 clinical results of its internally developed PD-1/VEGF bispecific antibody, ivonescimab, with or...

2024-09-15 15:10 4496

CNOOC Limited Successfully Withstands Super Typhoon "Yagi"

HONG KONG, Sept. 15, 2024 /PRNewswire/ -- CNOOC Limited (the "Company", SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) announces today that thanks to the Company's continuous focus on safety and environmental protection performance, as well as its mature typhoon response measures...

2024-09-15 10:41 8731

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

NANJING, China, Sept. 14, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation by the U...

2024-09-14 19:43 5374

Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)

* In Phase Ia clinical study, GZR4 demonstrated favorable safety and tolerability profiles in healthy subjects, maintaining a stable glucose-lowering effect for up to one week with a single administration. * In Phase Ib clinical study, patients with Type 2 diabetes mellitus (T2DM) receiving s...

2024-09-14 19:00 5952

TIME, Statista Name Three SM companies Among World's Best Companies

PASAY CITY, Philippines, Sept. 14, 2024 /PRNewswire/ -- TIME Magazine and Statista have recognized SM Investments Corporation, SM Prime Holdings, and China Banking Corporation as among the World's Best Companies for 2024. This accolade underscores the group's focus and exceptional performance in ...

2024-09-14 17:04 5863

Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Sept. 14, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immuno...

2024-09-14 16:06 5278